These breakthroughs launched a fleet of clinical trials designed to test the safety and efficacy of the DOT1L inhibitor Pinometostat (EPZ-5676) in patients with MLL-rearranged leukaemia (28, 29). The gene discussed is KMT2A; the disease is leukemia.